BiomX (NYSEAMERICAN:PHGE) Shares Up 1.5% – What’s Next?

BiomX Inc. (NYSEAMERICAN:PHGE) shares rose 1.5% during mid-day trading on Thursday . The company traded as high as $0.2825 and last traded at $0.28. Approximately 30,150,275 shares were traded during trading, an increase of 676% from the average daily volume of 3,883,265 shares. The stock had previously closed at $0.2758.

BiomX Stock Performance

The firm has a market cap of $3.30 million, a P/E ratio of -0.09 and a beta of 1.30. The firm has a 50 day simple moving average of $0.64 and a 200 day simple moving average of $2.76.

BiomX (NYSEAMERICAN:PHGE) last announced its quarterly earnings results on Wednesday, May 20th. The company reported $7.38 earnings per share for the quarter. Sell-side analysts predict that BiomX Inc. will post -5.85 EPS for the current fiscal year.

Hedge Funds Weigh In On BiomX

An institutional investor recently bought a new stake in BiomX stock. Alyeska Investment Group L.P. bought a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned 5.99% of BiomX at the end of the most recent quarter. Institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.